Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P06730

UPID:
IF4E_HUMAN

ALTERNATIVE NAMES:
eIF-4F 25 kDa subunit; mRNA cap-binding protein

ALTERNATIVE UPACC:
P06730; B7Z6V1; D6RCQ6; Q96E95

BACKGROUND:
The Eukaryotic translation initiation factor 4E, or EIF4E, is essential for the early steps of protein synthesis. As a component of the eIF4F complex, it binds to the mRNA cap, aiding in mRNA recognition and ribosome recruitment. Beyond its primary role, EIF4E participates in translational repression and mRNA storage, highlighting its multifaceted function in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Given EIF4E's critical role in EIF4E deregulation associated with Autism 19, targeting this protein could offer novel therapeutic avenues. The protein's involvement in disease pathogenesis, particularly through increased promoter activity leading to autism, underscores its potential as a therapeutic target.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.